Literature DB >> 10537954

Recent advances in the methods of cost-benefit analysis in healthcare. Matching the art to the science.

E McIntosh1, C Donaldson, M Ryan.   

Abstract

This paper outlines recent advances in the methods of cost-benefit analysis (CBA). Economic evaluations in healthcare can be criticised for, amongst other things, the inappropriate use of incremental cost-effectiveness ratios and the reporting of benefits in terms of cost savings, such as treatment costs averted. Many such economic evaluations are, according to the 'scientific' definition, CBAs. The 'balance-sheet' (or opportunity cost) approach is a form of CBA which can be used to identify who bears the costs and who reaps the benefits from any change. Whilst the next stage in a CBA, as defined in health economics, would require that all costs and benefits be valued in monetary terms, the balance-sheet approach, however, advocates that available monetary values can be augmented by other measures of cost and benefit. As such, this approach, which has a theoretical basis, is proposed as a practical prescription for CBA and highlights the notion that unquantified benefits are important and can be included within CBAs even when monetarisation is not possible. Recent methodological developments in monetary valuation for use in CBA are the development of the technique of willingness to pay, the use of conjoint analysis (CA) to elicit willingness-to-pay (WTP) values and advances in the debate on the inclusion of production gains in CBAs. Whilst acknowledging that there have been developments in each of these areas, it is claimed there has also been progress in using CBA as a framework for evaluation, as reflected by the balance-sheet approach. The paper concludes by stating that almost all types of economic evaluation have an element of the 'cost-benefit' approach in them. The important issue is to focus on the policy question to be addressed and to outline the relevant costs and benefits in a manner which assists the evaluation of welfare changes resulting from changes in healthcare delivery. The focus should not be on moulding a question to fit a hybrid definition of an analytical technique.

Mesh:

Year:  1999        PMID: 10537954     DOI: 10.2165/00019053-199915040-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  30 in total

1.  Assessing community values in health care: is the 'willingness to pay' method feasible?

Authors:  C Donaldson; S Farrar; T Mapp; A Walker; S Macphee
Journal:  Health Care Anal       Date:  1997-03

2.  The friction cost method for measuring indirect costs of disease.

Authors:  M A Koopmanschap; F F Rutten; B M van Ineveld; L van Roijen
Journal:  J Health Econ       Date:  1995-06       Impact factor: 3.883

Review 3.  Cost-effectiveness ratios: in a league of their own.

Authors:  S Birch; A Gafni
Journal:  Health Policy       Date:  1994-05       Impact factor: 2.980

Review 4.  Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?

Authors:  S Birch; A Gafni
Journal:  J Health Econ       Date:  1992-10       Impact factor: 3.883

5.  Using conjoint analysis to assess women's preferences for miscarriage management.

Authors:  M Ryan; J Hughes
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

6.  The cost-benefit approach.

Authors:  A Williams
Journal:  Br Med Bull       Date:  1974-09       Impact factor: 4.291

7.  Should college students be vaccinated against meningococcal disease? A cost-benefit analysis.

Authors:  L A Jackson; A Schuchat; R D Gorsky; J D Wenger
Journal:  Am J Public Health       Date:  1995-06       Impact factor: 9.308

8.  Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.

Authors:  D B Mark; M A Hlatky; R M Califf; C D Naylor; K L Lee; P W Armstrong; G Barbash; H White; M L Simoons; C L Nelson
Journal:  N Engl J Med       Date:  1995-05-25       Impact factor: 91.245

9.  Cost-effectiveness of routine coronary angiography after acute myocardial infarction.

Authors:  K M Kuntz; J Tsevat; L Goldman; M C Weinstein
Journal:  Circulation       Date:  1996-09-01       Impact factor: 29.690

10.  Cost-benefit analysis.

Authors:  R Robinson
Journal:  BMJ       Date:  1993-10-09
View more
  22 in total

1.  Health economic evaluation.

Authors:  A Shiell; C Donaldson; C Mitton; G Currie
Journal:  J Epidemiol Community Health       Date:  2002-02       Impact factor: 3.710

Review 2.  Cost effectiveness of screening for Chlamydia trachomatis: a review of published studies.

Authors:  E Honey; C Augood; A Templeton; I Russell; J Paavonen; P-A Mårdh; A Stary; B Stray-Pedersen
Journal:  Sex Transm Infect       Date:  2002-12       Impact factor: 3.519

3.  Value for money of changing healthcare services? Economic evaluation of quality improvement.

Authors:  J L Severens
Journal:  Qual Saf Health Care       Date:  2003-10

4.  The measurement of contingent valuation for health economics.

Authors:  Ahmed M Bayoumi
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

5.  The impact of health economics on healthcare delivery. A primary care perspective.

Authors:  D P Kernick
Journal:  Pharmacoeconomics       Date:  2000-10       Impact factor: 4.981

6.  The CarerQol instrument: a new instrument to measure care-related quality of life of informal caregivers for use in economic evaluations.

Authors:  W B F Brouwer; N J A van Exel; B van Gorp; W K Redekop
Journal:  Qual Life Res       Date:  2006-08       Impact factor: 4.147

7.  Using discrete choice experiments within a cost-benefit analysis framework: some considerations.

Authors:  Emma McIntosh
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

8.  Mapping ASTI patient's therapeutic-data model to virtual Medical Record: can VMR represent therapeutic data elements used by ASTI in clinical guideline implementations?

Authors:  Vahid Ebrahiminia; Mobin Yasini; Jean Baptiste Lamy
Journal:  AMIA Annu Symp Proc       Date:  2013-11-16

9.  Discretely Integrated Condition Event (DICE) Simulation for Pharmacoeconomics.

Authors:  J Jaime Caro
Journal:  Pharmacoeconomics       Date:  2016-07       Impact factor: 4.981

10.  The business case for quality improvement.

Authors:  Hannah Ryan Fischer; Scott Davis Duncan
Journal:  J Perinatol       Date:  2020-03-30       Impact factor: 2.521

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.